Improvement in QoL With
Natalizumab in Active CD
•Randomized, double-blind, placebo-controlled study of
–248 patients
•Mean IBDQ compared with placebo at Week 6
–Natalizumab 3 mg/kg at Week 0 (p=0.008)
–Natalizumab 3 mg/kg at Week 0 and Week 4 (p<0.001)
–Natalizumab 6 mg/kg at Week 0 and Week 4 (p<0.001)
•Patients receiving 2 infusions of natalizumab
–Statistically greater improvement in all 4 IBDQ dimensions compared with placebo (p<0.05)
Rutgeerts P et al. Gastroenterology. 2003;124:A378. Abstract M1585.